Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)’s share price gapped up before the market opened on Friday . The stock had previously closed at $3.80, but opened at $4.01. Marinus Pharmaceuticals shares last traded at $4.10, with a volume of 5,463,517 shares changing hands.
A number of equities analysts have commented on MRNS shares. ValuEngine raised Marinus Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, July 25th. JMP Securities restated an “outperform” rating and issued a $11.00 price target (up from $5.00) on shares of Marinus Pharmaceuticals in a research report on Tuesday, September 12th.
The company’s market cap is $106.91 million. The stock’s 50 day moving average is $2.81 and its 200 day moving average is $1.77.
Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.06. On average, equities analysts anticipate that Marinus Pharmaceuticals, Inc. will post ($0.74) EPS for the current year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. KCG Holdings Inc. raised its stake in Marinus Pharmaceuticals by 29.5% during the first quarter. KCG Holdings Inc. now owns 64,539 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 14,692 shares during the period. Jennison Associates LLC grew its position in Marinus Pharmaceuticals by 108.1% in the 2nd quarter. Jennison Associates LLC now owns 811,665 shares of the biopharmaceutical company’s stock worth $1,112,000 after purchasing an additional 421,600 shares during the last quarter. Granite Point Capital Management L.P. bought a new position in Marinus Pharmaceuticals in the 1st quarter worth about $1,372,000. Finally, Nexthera Capital LP bought a new position in Marinus Pharmaceuticals in the 1st quarter worth about $1,416,000. Hedge funds and other institutional investors own 28.76% of the company’s stock.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
Receive News & Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.